Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × enfortumab vedotin × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Transitional Cell 9 Urinary Bladder Neoplasms 3 Urethral Neoplasms 1 Ureteral Neoplasms 1 Peripheral Nervous System Diseases 1 Neoplasm Metastasis 1 Muscle-invasive Bladder Cancer 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Metastatic Urothelial Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Bladder Cancer 1

Interventions

pembrolizumab 20 Specimen Handling 12 Paclitaxel 11 Magnetic Resonance Spectroscopy 11 Carboplatin 11 Biopsy 10 olaparib 7 Gemcitabine 5 Capecitabine 5 130-nm albumin-bound paclitaxel 5 eribulin 4 Taxes 4 Doxorubicin 4 X-Rays 3 Nivolumab 3 Cyclophosphamide 3 Cisplatin 3 tucatinib 2 sargramostim 2 liposomal doxorubicin 2 durvalumab 2 ceralasertib 2 Trastuzumab 2 Standard of Care 2 Platinum 2 Immunoglobulin G 2 Fulvestrant 2 Drug Therapy 2 Docetaxel 2 Colony-Stimulating Factors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡